Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

RSCRC scientists explore mysteries of human embryonic stem cells

At Rutgers' Stem Cell Research Center scientists are exploring the mysteries of human embryonic stem cells and their potential use in treating diseases, repairing damaged organs, and drug development. Center staff also offer a course in proper lab techniques in working with stem cells.

17 Apr 2010

New data on Cladribine Tablets presented at AAN annual meeting

EMD Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that new data providing further understanding on Cladribine Tablets as a potential new therapeutic option for relapsing forms of multiple sclerosis were presented at the 62nd Annual Meeting of the American Academy of Neurology.

17 Apr 2010

FDA approves BioAlliance Pharma's Oravig for OPC

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.

17 Apr 2010

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has entered into a Cooperative Research and Development Agreement with the Naval Medical Research Center. NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria.

16 Apr 2010

Smoking may increase risk of MS in people who have established risk factors for MS

A new study shows that smoking may increase the risk of multiple sclerosis in people who also have specific established risk factors for MS. The research is found in the April 7, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Apr 2010

StockPreacher.com: GenVec's revenues for 2009 decline by 8%

StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

Nationwide Phase III clinical trial of OncoVEX for advanced melanoma

Rush University Medical Center is leading a nationwide Phase III clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer.

7 Apr 2010

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine -targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research.

6 Apr 2010

BioAlliance Pharma SA signs partnership agreement with Therabel Group

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc® and Setofilm® including France and the associated French commercial structure to a newly established entity, Therabel Hôpital Pharma.

6 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Backpacker problem in Australia - binge drinking and unprotected sex

The tourist season may not be quite as healthy for the locals as it was before. In an eight year old study conducted by the Sydney Sexual Health Care Centre some scary facts have come to light. The study was based on about 5,700 backpackers who belonged mostly to the UK or Ireland and were in their mid twenties.

28 Mar 2010

Merix Pharmaceutical introduces new Fast-Results! Genital Herpes Treatment

Merix Pharmaceutical Corp. unveiled its new Fast-Results!™ Genital Herpes Treatment March 1st while attending a retail industry trade show in Dallas. The first ever OTC treatment for genital herpes, Fast-Results! answers the unmet need of people who suffer painful symptoms caused by the herpes virus.

23 Mar 2010

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2009 and provided an update on various corporate developments.

23 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Black children less likely to develop shingles after receiving chickenpox vaccine

Black children are less likely than white or Asian children to develop shingles (herpes zoster) after receiving the varicella vaccine to prevent chickenpox, reports a study in the March issue of The Pediatric Infectious Disease Journal.

17 Mar 2010